1. Home
  2. TRIP vs REPL Comparison

TRIP vs REPL Comparison

Compare TRIP & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TripAdvisor Inc.

TRIP

TripAdvisor Inc.

N/A

Current Price

$7.28

Market Cap

1.2B

Sector

Technology

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$21.91

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRIP
REPL
Founded
2000
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2011
2018

Fundamental Metrics

Financial Performance
Metric
TRIP
REPL
Price
$7.28
$21.91
Analyst Decision
Hold
Buy
Analyst Count
16
8
Target Price
$11.57
★ $23.33
AVG Volume (30 Days)
★ 5.7M
3.2M
Earning Date
11-05-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 675.00
N/A
EPS
N/A
★ N/A
Revenue
★ $1,556,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$513.15
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.78
$1.50
52 Week High
$15.73
$23.64

Technical Indicators

Market Signals
Indicator
TRIP
REPL
Relative Strength Index (RSI) 35.11 70.94
Support Level N/A $7.19
Resistance Level $11.53 N/A
Average True Range (ATR) 0.52 1.67
MACD -0.20 0.42
Stochastic Oscillator 12.12 82.86

Price Performance

Historical Comparison
TRIP
REPL

About TRIP TripAdvisor Inc.

Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025. The company is selling TheFork, its dining brand, which represented 12% of sales.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: